Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 2: 277 - 288

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231018.001

Gehua Jiejiu Dizhi decoction (葛花解酒涤脂汤) ameliorates alcoholic fatty liver in mice by regulating lipid and bile acid metabolism and with exertion of antioxidant stress based on 4DLabel-free quantitative proteomic study

  • Min HAN ,
  • Xu YI ,
  • Shaowei YOU ,
  • Xueli WU ,
  • Shuoshi WANG ,
  • Diancheng HE
Expand
  • 1 Guizhou University of Traditional Chinese Medicine, Graduate School, Guiyang 550025, China
    2 Department of Clinical medical laboratory, Department of Gastroenterology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003, China

Received date: 2022-11-11

  Accepted date: 2023-04-27

  Online published: 2023-12-18

Supported by

National Science Foundation-funded Project: the Study on the Changes of Energy Metabolism and Molecular Regulation Mechanism of Alcoholic Fatty Liver based on Sirtuins1-Adenosine Monophosphate-Activated Protein Kinase Signal System and the Intervention of Gehua Jiejiu dizhi decoction(81660752);Basic Research Project of Guizhou Provincial Science and Technology Plan: Study on the Mechanism of Sirtuins1 Mediated Deacetylation in the Regulation of Alcoholic Fatty Liver Metabolism and the Intervention of Gehua Jiejiu Dizhi Tang(QianKeHe Fundamentals-ZK [2023] General 410)

Fold

Abstract

OBJECTIVE: To analyze the effect and molecular mechanism of Gehua Jiejiu Dizhi decoction (葛花解酒涤脂汤, GJDD) on alcoholic fatty live disease (AFLD) by using proteomic methods.

METHODS: The male C57BL/6J mouse were randomly divided into four groups: control group, model group, GJDD group and resveratrol group. After the AFLD model was successfully prepared by intragastric administration of alcohol once on the basis of the Lieber-DeCarli classical method, the GJDD group and resveratrol group were intragastrically administered with GJDD (4900 mg/kg) and resveratrol (400 mg/kg) respectively, once a day for 9 d. The fat deposition of liver tissue was observed and evaluated by oil red O (ORO) staining. 4DLabel-free quantitative proteome method was used to determine and quantify the protein expression in liver tissue of each experimental group. The differentially expressed proteins were screened according to protein expression differential multiples, and then analyzed by Gene ontology classification and Kyoto Encyclopedia of Genes and Genomes pathway enrichment. Finally, expression validation of the differentially co-expressed proteins from control group, model group and GJDD group were verified by targeted proteomics quantification techniques.

RESULTS: In semiquantitative analyses of ORO, all kinds of steatosis (ToS, MaS, and MiS) were evaluated higher in AFLD mice compared to those in GJDD or resveratrol-treated mice. 4DLabel-free proteomics analysis results showed that a total of 4513 proteins were identified, of which 3763 proteins were quantified and 946 differentially expressed proteins were screened. Compared with the control group, 145 proteins were up-regulated and 148 proteins were down-regulated in the liver tissue of model group. In addition, compared with the model group, 92 proteins were up-regulated and 135 proteins were down-regulated in the liver tissue of the GJDD group. 15 differentially co-expressed proteins were found between every two groups (model group vs control group, GJDD group vs model group and GJDD group vs control group), which were involved in many biological processes. Among them, 11 differentially co-expressed key proteins (Aox3, H1-5, Fabp5, Ces3a, Nudt7, Serpinb1a, Fkbp11, Rpl22l1, Keg1, Acss2 and Slco1a1) were further identified by targeted proteomic quantitative technology and their expression patterns were consistent with the results of 4D label-free proteomic analysis.

CONCLUSIONS: Our study provided proteomics-based evidence that GJDD alleviated AFLD by modulating liver protein expression, likely through the modulation of lipid metabolism, bile acid metabolism and with exertion of antioxidant stress.

Key words： fatty liver, alcoholic; 4DLabel-free quantitative proteome; targeted protein quantification; Gehua Jiejiu Dizhi decoction

Cite this article

Min HAN , Xu YI , Shaowei YOU , Xueli WU , Shuoshi WANG , Diancheng HE . Gehua Jiejiu Dizhi decoction (葛花解酒涤脂汤) ameliorates alcoholic fatty liver in mice by regulating lipid and bile acid metabolism and with exertion of antioxidant stress based on 4DLabel-free quantitative proteomic study[J]. Journal of Traditional Chinese Medicine, 2024 , 44(2) : 277 -288 . DOI: 10.19852/j.cnki.jtcm.20231018.001

References

1. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018; 4: 16-38.
2. Zeng T, Zhang CL, Zhao N, et al. Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver. Redox Biol 2018; 14: 295-304.
3. Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23: 6549-70.
4. Ding QX, Wang DX, Zhang XH. Research progress of Traditional Chinese Medicine in treatment of alcoholic fatty liver. Grassroots Medical Forum 2017; 21: 2124-26.
5. Wu XL, Feng X, Hao J, Yi X. Study on anti-alcoholic fatty liver effect of Gehua Jiejiu Dizhi decoction based on network pharmacology. Anhui Yi Ke Da Xue Xue Bao 2022; 57: 260-4.
6. Yi X, You SW, Long Y, Wang SS, Lu DM. Intervention Effect of Gehua Jiejiu Dizhi decoction on alcoholic fatty liver and liver PXR, CAR expression in mice. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2016; 22: 134-9.
7. Yi X, You SW, Long Y, Wang SS, Lu DM. Effect of Gehua Jiejue Dizhi decoction on the liver fatty deposition and expression of PXR in the mouse alcoholic fatty liver. Zhong Guo Bi Jiao Yi Xue Za Zhi 2017; 27: 36-42.
8. Yi X, Wang SS, Hao J, You SW, Zhan YM. Detection of LXRα-SREBP -1c signaling expression in liver of alcoholic fatty liver mice and intervention of Gehua Jiejiu Dizhi decoction. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2021; 39: 13-6+261.
9. Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci 2017; 60: 1093-113.
10. Liu S, Li Z, Yu B, Wang S, Shen Y, Cong H. Recent advances on protein separation and purification methods. Adv Colloid Interface Sci 2020; 284: 102254-64.
11. Yang L, Yang C, Thomes PG, et al. Lipophagy and alcohol-induced fatty liver. Front Pharmacol 2019; 10: 495-508.
12. Banerjee A, Russell WK, Jayaraman A, Ramaiah SK. Identification of proteins to predict the molecular basis for the observed gender susceptibility in a rat model of alcoholic steatohepatitis by 2-D gel proteomics. Proteomics 2008; 8: 4327-37.
13. Fernando H, Wiktorowicz JE, Soman KV, Kaphalia BS, Khan MF, Shakeel Ansari GA. Liver proteomics in progressive alcoholic steatosis. Toxicol Appl Pharmacol 2013; 266: 470-80.
14. Klouckova I, Hrncirova P, Mechref Y, et al. Changes in liver protein abundance in inbred lcohol-preferring rats due to chronic alcohol exposure, as measured through a proteomics approach. Proteomics 2006; 6: 3060-74.
15. Swart PC, Russell VA, Vlok NM, Dimatelis JJ. Early-ethanol exposure induced region-specific changes in metabolic proteins in the rat brain: a proteomics study. J Mol Neurosci 2018; 65: 277-88.
16. Aebersold R, Matthias M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
17. Song P, Shen X. Proteomic analysis of liver in diet-induced Hyperlipidemic mice under Fructus Rosa roxburghii action. J Proteomics 2021; 230: 103982-94.
18. Dai J, Liang K, Zhao S, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci USA 2018; 115: E5896-905.
19. Du Y, Cai T, Li T, et al. Lysine malonylation is elevated in type 2 diabetic mouse models and enriched in metabolic associated proteins. Mol Cell Proteomics 2015; 14: 227-36.
20. Liu B, Jiang S, Li M, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN. Nat Commun 2018; 9: 4770-82.
21. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013; 8: 627-37.
22. You M, Jogasuria A, Taylor C, Wu J. Sirtuin 1 signaling and alcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015; 4: 88-100.
23. Ren R, Wang Z, Wu M, Wang H. Emerging roles of SIRT1 in alcoholic liver disease. Int J Biol Sci 2020; 16: 3174-83.
24. He PY, Hou ZP, Song CJ, Wang CQ, Li BQ, Mustapha UI. Resveratrol ameliorates experimental alcoholic liver disease by modulating oxidative stress. Evid Based Complement Alternat Med 2017; 2017: 4287890-901.
25. Tang L, Yang F, Fang Z, Hu C. Resveratrol ameliorates alcoholic fatty liver by inducing autophagy. Am J Chin Med 2016; 44: 1207-20.
26. Chen WM, Shaw LH, Chang PJ, et al. Hepatoprotective effect of resveratrol against ethanol-induced oxidative stress through induction of superoxide dismutase in vivo and in vitro. Exp Ther Med 2016; 11: 1231-8.
27. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible. J Hepatol 2011; 54: 1055-62.
28. Reis H, Peterek PT, Wohlschlaeger J, et al. Oil Red O-assessed macrosteatosis in liver transplantdonor biopsies predicts ischemia-reperfusion injury and clinical outcome. Virchows Arch 2014; 464: 165-74.
29. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-13.
30. Sun XZ, Wang D, Ding L, et al. Activation of autophagy through the NLRP3/mTOR pathway: a potential mechanism for alleviation of pneumonia by Qingfei Yin. Front Pharmacol 2021; 12: 763160-77.
31. Li X, Wu D, Niu J, et al. Intestinal Flora: a pivotal role in investigation of Traditional Chinese Medicine. Am J Chin Med 2021; 49: 237-68.
32. Liang B, Gu N. Traditional Chinese Medicine for coronary artery disease treatment: clinical evidence from randomized controlled trials. Front Cardiovasc Med 2021; 8: 702110-9.
33. Yao ZS, Wu Y, Zhao HX, et al. Treatment of alcoholic liver disease with TCM. Heman Zhong Yi Yao Xue Bao 2020; 40: 1941-4.
34. Elken H, Xie JR, Liang GY, et al. Research progress of Traditional Chinese Medicine in the treatment of fatty liver disease. Liaoning Zhong Yi Yao Da Xue Xue Bao 2020; 22: 92-5.
35. Ding XW, Xu YF, Nie P, et al. Changes in the serum metabolomic profiles of subjects with NAFLD in response to n-3 PUFAs and phytosterol ester: a double-blind randomized controlled trial. Food funct 2022; 13: 5189-201.
36. Zhu S, Zhang J, Zhu D, et al. Adipose tissue plays a major role in retinoic acid-mediated metabolic homoeostasis. Adipocyte 2022; 11: 47-55.
37. Errafii K, Al-Akl NS, Khalifa O, Arredouani A. Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J Transl Med 2021; 19: 235-46.
38. Lian J, Nelson R, Lehner R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell 2018; 9: 178-95.
39. Dominguez E, Galmozzi A, Chang JW, et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat Chem Biol 2014; 10: 113-21.
40. Mukherjee S, Choi M, Yun JW. Novel regulatory roles of carboxylesterase 3 in lipid metabolism and browning in 3T3-L1 white adipocytes. Appl Physiol Nutr Metab 2019; 44: 1089-98.
41. Yang L, Li X, Tang H, Gao Z, Zhang K, Sun K. A unique role of carboxylesterase 3 (Ces3) in beta-adrenergic signaling-stimulated thermogenesis. Diabetes 2019; 68: 1178-96.
42. Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr 2018; 18: 71-87.
43. Zhang Y, Limaye PB, Lehman-McKeeman LD, Klaassen CD. Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. PLoS One 2012; 7: e34522-33.
44. Zhang T, Li J, Liu CP, et al. Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia an inhibiting liver gasdermin D-mediated pyroptosis. Ann Transl Med 2021; 9: 873-87.
45. Zhang Y, Csanaky IL, Cheng X, Lehman-McKeeman LD, Klaassen CD. Organic anion transporting polypeptide 1a1 null mice are sensitiveto cholestatic liver injury. Toxicol Sci 2012; 127: 451-62.
46. Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology (Baltimore, Md) 2018; 67: 2150-66.
47. Jiang L, Chu HK, Gao B, et al. Transcriptomic profiling identifies novel hepatic and intestinal genes following chronic plus binge ethanol feeding in mice. Dig Dis Sci 2020; 65: 3592-604.
48. Moore SM, Holt VV, Malpass LR, Hines IN, Wheeler MD. Fatty acid-binding protein 5 limits the anti-inflammatory response in murine macrophages. Mol Immunol 2015; 67: 265-75.
49. Babaev VR, Runner RP, Fan D, et al. Macrophage Mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-gamma-regulated genes. Arterioscler Thromb Vasc Biol 2011; 31: 1283-90.
50. Matsuo M, Terai K, Kameda N, et al. Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma. Biochem Biophys Res Commun 2012; 420: 901-6.
51. Shumar SA, Kerr EW, Geldenhuys WJ, et al. Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 2018; 293: 4134-48.
52. Shumar SA, Kerr EW, Fagone P, Infante AM, Leonardi R. Overexpression of Nudt7 decreases bile acid levels and peroxisomal fatty acidoxidation in the liver. J Lipid Res 2019; 60: 1005-19.
53. Naquet P, Kerr EW, Vickers SD, Leonardi R. Leonardi R. Regulation of coenzyme A levels by degradation: the 'Ins and Outs'. Prog Lipid Res 2020; 78: 101028-72.
54. Gasmi L, McLennan AG. The mouse Nudt7 gene encodes a peroxisomal nudix hydrolase specific for coenzyme A and its derivatives. Biochem J 2001; 357: 33-8.
55. Leonardi R, Rock CO, Jackowski S. Pank1 deletion in leptin-deficient mice reduces hyperglycaemia and hyperinsulinaemia and modifies global metabolism without affecting insulin resistance. Diabetologia 2014; 57: 1466-75.
56. Leonardi R, Rehg JE, Rock CO, Jackowski S. Pantothenate kinase 1 is required to support the metabolic transition from the fed to the fasted state. PLoS One 2010; 5: e11107-19.
57. Kryvalap Y, Czyzyk J. The Role of proteases and serpin protease inhibitors in β-cell biology and diabetes. Biomolecules 2022; 12: 67-77.
58. Liang X, Su Y, Huo Y. Forkhead box protein O1 (FoxO1) /SERPINB 1 ameliorates ROS production in diabetic nephropathy. Food Sci Nutr 2020; 9: 44-51.
59. Xing YQ, Li A, Yang Y, Li XX, Zhang LN, Guo HC. The regulation of FOXO1 and its role in disease progression. Life Sci 2018; 193: 124-131.
60. Chen J, Lu Y, Tian M, Huang Q. Molecular mechanisms of FOXO1 in adipocyte differentiation. J Mol Endocrinol 2019; 62: R239-53.
61. Skat-R?rdam J, H?jland Ipsen D, Lykkesfeldt J, Tveden-Nyborg P. A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 2019; 124: 528-37.
62. Huang Z, Zhang M, Plec AA, et al. ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism. Proc Natl Acad Sci USA 2018; 115: E9499-506.
63. Martínez-Micaelo N, González-Abuín N, Terra X, et al. Identification of a nutrient-sensing transcriptional network in monocytes by using inbred rat models on a cafeteria diet. Dis Model Mech 2016; 9: 1231-9.
64. Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol 2014; 20: 14672-85.
65. Terao M, Garattini E, Rom?o MJ, Leimkühler S. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J Biol Chem 2020; 295: 5377-89.
66. Zhong G, Seaman CJ, Paragas EM, et al. Aldehyde oxidase contributes to all-trans-retinoic acid biosynthesis in human liver. Drug Metab Dispos 2021; 49: 202-11.
67. Zarei L, Farhad N, Abbasi A. All-trans retinoic acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis. Arch Physiol Biochem 2020: 1-6.
68. Tsuchiya H. Retinoids as promising treatment for non-alcoholic fatty liver disease. Yakugaku Zasshi 2012; 132: 903-9.
69. Lin IY, Yen CH, Liao YJ, et al. Identification of FKBP11 as a biomarker for hepatocellular carcinoma. Anticancer Research 2013; 33: 2763-9.
70. Momeni M, Kalir T, Farag S, Chuang L, Fishman D, Burstein DE. Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cellular Oncology (Dordrecht) 2014; 37: 229-34.
71. Rao S, Peri S, Hoffmann J, et al. RPL22L 1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS One 2019; 14: e0222392-412.
Options
Outlines

/

〈 〉